Aurion Biotech

Executive Summary

Aurion Biotech is a private, early-stage biotechnology company focused on developing first-in-class cell and gene therapies to treat blindness and vision loss. Founded in 2021 and headquartered in Seattle, WA and Cambridge, MA, the company leverages global expertise in ophthalmology, regenerative medicine, and drug development to advance innovative therapies. Currently in Phase 1/2 clinical development, Aurion's lead program targets a major cause of blindness, aiming to restore vision through a novel mechanism. The company's platform holds potential for multiple indications, and its progress is closely watched given the large unmet need in ophthalmology. With a strong scientific foundation and a clear mission to eliminate blindness, Aurion Biotech represents a promising but early-stage investment opportunity in the cell and gene therapy space.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 interim data readout for lead candidate45% success
• Q1 2027IND filing for second pipeline candidate60% success
• H2 2026Potential strategic partnership or licensing deal for Asian markets35% success